Results
1 -
10 of
82Attila A. SeyhanCurrent address: Pfizer Inc., Translational Immunology, Inflammation and Immunology, 200 Cambridgepark Drive, Cambridge, MA 02140, USA., Usha Varadarajan, Sung Choe, Yan Liu, John McGraw, Matthew Woods, Stuart Murray, Amy Eckert, Wei Liu and Terence E. Ryan.
A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments, Mol. Biosyst., 2011, 7, 1974. Attila A. SeyhanCurrent address: Pfizer Inc., Translational Immunology, Immunology and Autoimmunity, 200 Cambridgepark Drive, Cambridge, MA 02140, USA., Usha Varadarajan, Sung ChoeCurrent address: Agi
os Pharmaceuticals, Cambridge, MA 02139, USA., Wei Liu and Terence E. Ryan.
A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers, Mol. Biosyst., 2012, 8, 1553. EGFR Mutant Lung Cancer, Therapeutic Kinase Inhibitors HER2/neu, Cancer Therapeutic Targets Tyrosine Kinase Inhibitors, Breast Disease Emerging Targeted Agents for HER2-Positive Breast Cancer, Handbook of HER2-targeted agents in breast cancer Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update, Lung Cancer and Personalized Medicine Beyond Trastuzumab: Second-Generation Targeted Therapies for HER-2-positive Breast Cancer, Drugs for HER-2-positive Breast Cancer HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies, PI3K-mTOR in Cancer and Cancer Therapy Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer, Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways